Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin as adjunctive therapy for active rheumatoid arthritis
IRCT20260715070199N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Standard RA treatment + azithromycin with Standard RA treatment + placebo (2 arms). Primary endpoints: Disease Activity Score 28, Clinical Disease Activity Index and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
azithromycin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on IRCT20260715070199N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260715070199N1.